Risk Factors Update Summary

• Accumulated deficit increased from $287 million to $369 million, impacting financial position significantly.
• Termination of Roche Collaboration Agreement in April 2024, impacting future collaborations.
• Addition of regulatory investigations to security measures, increasing vulnerability to cyber attacks.
• The EU GDPR ceased to apply in the UK, potentially increasing legal risk and complexity.
• The UK GDPR may become less aligned with the EU GDPR, impacting data handling.
• Increased risks from cyber threats including ransomware, phishing, and power outages.
• Net loss increased from $64.9 million to $81.6 million, indicating a decline in financial performance.
• Strategic refocus led to a 30% reduction in workforce and discontinued projects, affecting operations.
• New standard contractual clauses issued for data transfers to the United States.
• Remote work increases cybersecurity risks, especially with acquisitions exposing to vulnerabilities.
• Cash, cash equivalents, and restricted cash increased from $117 million to $5 million, affecting liquidity.
• Entered into Stock Purchase Agreement with Gilead for $21.25 million, impacting ownership.
• The potential misalignment between future UK laws and EU laws could add legal risk.
• Received funds under Roche Collaboration Agreement in April 2024, impacting financial resources.
• A reduction in workforce by approximately 30% may disrupt operations and cost more than expected.
• Failure to comply with data privacy laws could lead to fines, penalties, and business disruptions.
• Increased costs due to workforce reduction and restructuring efforts may impact financial results.